PD-1 Non-Small Cell Lung Cancer Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | AstraZeneca, Seagen, MacroGenics, Roche, Qilu Pharmaceutical, Shandong New Age Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, PD-1 Non-Small Cell Lung Cancer pipeline constitutes 30+ key companies continuously working towards developing 30+ PD-1 Non-Small Cell Lung Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"PD-1 Non-Small Cell Lung Cancer Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PD-1 Non-Small Cell Lung Cancer Market.

The PD-1 Non-Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the PD-1 Non-Small Cell Lung Cancer Pipeline Report: https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel PD-1 Non-Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years.
• PD-1 Non-Small Cell Lung Cancer companies working in the treatment market are Summit Therapeutics, Arcus Biosciences, Pfizer, AstraZeneca, Seagen, Genor Biopharma, Shandong Boan Biotechnology, Pfizer, AstraZeneca, Lepu Biopharma, GlaxoSmithKline, Incyte Corporation, Akeso Biopharma, and others, are developing therapies for the PD-1 Non-Small Cell Lung Cancer treatment
• Emerging PD-1 Non-Small Cell Lung Cancer therapies in the different phases of clinical trials are- Ivonescimab, Zimberelimab, Sasanlimab, Rilvegostomig, SGN-PDL1V, GB226, BA-1104, PF-06801591, AZD2936, HX008, Dostarlimab, INCMGA00012, AK-112, and others are expected to have a significant impact on the PD-1 Non-Small Cell Lung Cancer market in the coming years.
• In June 2023, During the 2023 American Society of Clinical Oncology Annual Meeting (ASCO 2023), Qilu Pharmaceutical showcased a poster presentation highlighting the ongoing trials of QL1706 (iparomlimab/tuvonralimab), an inventive bifunctional antibody designed for immunotherapy. This presentation focused on its involvement in two Phase III clinical studies for non-small cell lung carcinoma (NSCLC).
• In May 2023, Summit Therapeutics has reported the enrollment of the first patient in the Phase III HARMONi study in the United States. This trial, classified as a Phase III multiregional, randomized, double-blinded study, aims to assess the effectiveness and safety of ivonescimab in combination with chemotherapy for individuals with epidermal growth factor receptor (EGFR)-mutated, locally advanced, or metastatic non-squamous non-small cell lung cancer (NSCLC) who have experienced progression following treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) like osimertinib.
• In May 2023, Gilead Sciences and Arcus Biosciences have revealed the latest findings from an interim analysis of the ARC-7 study involving patients with first-line metastatic non-small cell lung cancer (NSCLC) exhibiting a PD-L1 tumor proportion score (TPS) of 50% and lacking epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations. The progression-free survival curves depicted an early and sustained separation between both domvanalimab-containing arms and the zimberelimab arm, underscoring the potential therapeutic advantages associated with inhibiting the TIGIT pathway.
• In October 2022, Akeso Biopharma reported that the Breakthrough Therapy Designation (BTD) has been conferred by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for Ivonescimab (PD-1/VEGF bispecific antibody, AK112) in combination with docetaxel. This designation is granted for the treatment of patients with locally advanced or metastatic Non-Small-Cell Lung Carcinoma (NSCLC) who did not respond to previous PD-(L)1 inhibitor combined with platinum-based doublet chemotherapy.

PD-1 Non-Small Cell Lung Cancer Overview
PD-1, or programmed cell death protein 1, is a type of immune checkpoint protein found on the surface of certain immune cells called T cells. It plays a crucial role in regulating the immune system by preventing these cells from attacking other cells in the body indiscriminately. However, in the context of cancer, including non-small cell lung cancer (NSCLC), the interaction between PD-1 and its corresponding ligands can be exploited by cancer cells to evade the immune system.

Get a Free Sample PDF Report to know more about PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging PD-1 Non-Small Cell Lung Cancer Drugs Under Different Phases of Clinical Development Include:
• Ivonescimab: Summit Therapeutics
• Zimberelimab: Arcus Biosciences
• Sasanlimab: Pfizer
• Rilvegostomig: AstraZeneca
• SGN-PDL1V: Seagen
• GB226: Genor Biopharma
• BA-1104: Shandong Boan Biotechnology
• PF-06801591: Pfizer
• AZD2936: AstraZeneca
• HX008: Lepu Biopharma
• Dostarlimab: GlaxoSmithKline
• INCMGA00012: Incyte Corporation
• AK-112: Akeso Biopharma

PD-1 Non-Small Cell Lung Cancer Route of Administration
PD-1 Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

PD-1 Non-Small Cell Lung Cancer Molecule Type
PD-1 Non-Small Cell Lung Cancer Products have been categorized under various Molecule types, such as
• Monoclonal antibody
• Small molecule
• Peptide

PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment
• PD-1 Non-Small Cell Lung Cancer Assessment by Product Type
• PD-1 Non-Small Cell Lung Cancer By Stage and Product Type
• PD-1 Non-Small Cell Lung Cancer Assessment by Route of Administration
• PD-1 Non-Small Cell Lung Cancer By Stage and Route of Administration
• PD-1 Non-Small Cell Lung Cancer Assessment by Molecule Type
• PD-1 Non-Small Cell Lung Cancer by Stage and Molecule Type

DelveInsight's PD-1 Non-Small Cell Lung Cancer Report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further PD-1 Non-Small Cell Lung Cancer product details are provided in the report. Download the PD-1 Non-Small Cell Lung Cancer pipeline report to learn more about the emerging PD-1 Non-Small Cell Lung Cancer therapies at:
https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the PD-1 Non-Small Cell Lung Cancer Therapeutics Market include:
Key companies developing therapies for PD-1 Non-Small Cell Lung Cancer are - AstraZeneca, Seagen, MacroGenics, Roche, Qilu Pharmaceutical, Shandong New Age Pharmaceutical, Summit Therapeutics, Arcus Biosciences, GlaxoSmithKline, Pfizer, Symphogen, and others.

PD-1 Non-Small Cell Lung Cancer Pipeline Analysis:
The PD-1 Non-Small Cell Lung Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of PD-1 Non-Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PD-1 Non-Small Cell Lung Cancer Treatment.
• PD-1 Non-Small Cell Lung Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• PD-1 Non-Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PD-1 Non-Small Cell Lung Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about PD-1 Non-Small Cell Lung Cancer drugs and therapies-
https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

PD-1 Non-Small Cell Lung Cancer Pipeline Market Drivers
• Increase in Patient Burden, development of Efficient Novel Treatments, increasing healthcare expenditures are some of the important factors that are fueling the PD-1 Non-Small Cell Lung Cancer Market.

PD-1 Non-Small Cell Lung Cancer Pipeline Market Barriers
• However, uncertainty about the clinical response to PD-1/PD-L1 blockade therapy in NSCLC, NSCLC with driver mutations represent a challenging population and other factors are creating obstacles in the PD-1 Non-Small Cell Lung Cancer Market growth.

Scope of PD-1 Non-Small Cell Lung Cancer Pipeline Drug Insight
• Coverage: Global
• Key PD-1 Non-Small Cell Lung Cancer Companies: Summit Therapeutics, Arcus Biosciences, Pfizer, AstraZeneca, Seagen, Genor Biopharma, Shandong Boan Biotechnology, Pfizer, AstraZeneca, Lepu Biopharma, GlaxoSmithKline, Incyte Corporation, Akeso Biopharma, and others
• Key PD-1 Non-Small Cell Lung Cancer Therapies: Ivonescimab, Zimberelimab, Sasanlimab, Rilvegostomig, SGN-PDL1V, GB226, BA-1104, PF-06801591, AZD2936, HX008, Dostarlimab, INCMGA00012, AK-112, and others
• PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment: PD-1 Non-Small Cell Lung Cancer current marketed and PD-1 Non-Small Cell Lung Cancer emerging therapies
• PD-1 Non-Small Cell Lung Cancer Market Dynamics: PD-1 Non-Small Cell Lung Cancer market drivers and PD-1 Non-Small Cell Lung Cancer market barriers

Request for Sample PDF Report for PD-1 Non-Small Cell Lung Cancer Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. PD-1 Non-Small Cell Lung Cancer Report Introduction
2. PD-1 Non-Small Cell Lung Cancer Executive Summary
3. PD-1 Non-Small Cell Lung Cancer Overview
4. PD-1 Non-Small Cell Lung Cancer- Analytical Perspective In-depth Commercial Assessment
5. PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutics
6. PD-1 Non-Small Cell Lung Cancer Late Stage Products (Phase II/III)
7. PD-1 Non-Small Cell Lung Cancer Mid Stage Products (Phase II)
8. PD-1 Non-Small Cell Lung Cancer Early Stage Products (Phase I)
9. PD-1 Non-Small Cell Lung Cancer Preclinical Stage Products
10. PD-1 Non-Small Cell Lung Cancer Therapeutics Assessment
11. PD-1 Non-Small Cell Lung Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. PD-1 Non-Small Cell Lung Cancer Key Companies
14. PD-1 Non-Small Cell Lung Cancer Key Products
15. PD-1 Non-Small Cell Lung Cancer Unmet Needs
16 . PD-1 Non-Small Cell Lung Cancer Market Drivers and Barriers
17. PD-1 Non-Small Cell Lung Cancer Future Perspectives and Conclusion
18. PD-1 Non-Small Cell Lung Cancer Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

PD-1 Non-Small Cell Lung Cancer Market https://www.delveinsight.com/report-store/pd-1-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'PD-1 Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Latest Reports:
Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of heart failure and cardiovascular diseases due to obesity, age, & unhealthy lifestyles and rising demand for organ transplants due to increasing prevalence of chronic ailments such as hypertension, diabetes, and others

B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.